Bottom line
CHNA vs PRHSX: the short answer
CHNA (Loncar China BioPharma ETF) and PRHSX (T. Rowe Price Health Sciences Fund, Inc.) are both etfs.
Updated Nov 19, 2026
CHNA vs PRHSX side by side
| CHNA | PRHSX | |
|---|---|---|
| Type | ETF | Mutual fund |
| Fund family | Grayscale | T. Rowe Price |
| Category | Health Care Sector | Health Care Sector |
| Expense ratio | — | 0.83% |
| Annual cost per $10k | — | $83 |
| 10-yr cost on $10k (prospectus) | — | $1,025 |
| Max front load | None | — |
| 12b-1 fee | — | — |
| 1-yr return | — | +17.7% |
| 5-yr return (annualized) | — | +4.2% |
| 10-yr return (annualized) | — | +9.1% |
| Best quarter | — | +23.5% |
| Worst quarter | — | −15.8% |
| Net assets (fund) | — | $11.9B |
| Number of holdings | — | 279 |
| Portfolio turnover | — | 62% |
| Returns as of | — | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Holdings overlap
CHNA and PRHSX share none of their top holdings.
CHNA top 10
PRHSX top 10
- Eli Lilly & Co — 14.28%
- Johnson & Johnson — 6.63%
- Unitedhealth Group Inc — 5.99%
- Abbvie Inc — 5.10%
- Merck & Co. Inc. — 4.01%
- Gilead Sciences Inc — 2.82%
- Thermo Fisher Scientific Inc — 2.52%
- Vertex Pharmaceuticals Inc — 2.28%
- Bristol-myers Squibb Co — 2.11%
- Abbott Laboratories — 1.89%
FAQ
What is the difference between CHNA and PRHSX?
CHNA (Loncar China BioPharma ETF) and PRHSX (T. Rowe Price Health Sciences Fund, Inc.) are both etfs.
Should I own both CHNA and PRHSX?
Because their portfolios differ, owning both can add diversification — check how they fit your overall allocation.
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.